Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen in 16p11.2 Deletion Syndrome
NCT04271332Phase 2Active, not recruiting
- Sponsor
- Clinical Research Associates
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in 16p11.2 deletion syndrome comparing Arbaclofen with Placebo (2 arms). Primary endpoint: Goldman-Fristoe Test of Articulation, 3rd edition, Sounds-in-Words at 12 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
arbaclofen
03
Conditions
16p11.2 deletion syndrome
Beyond the preview
Go deeper on NCT04271332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271332.